ACAD
ACADIA Pharmaceuticals Inc
NASDAQ: ACAD · HEALTHCARE · BIOTECHNOLOGY
$22.20
-2.07% today
Updated 2026-04-29
Market cap
$3.80B
P/E ratio
9.65
P/S ratio
3.55x
EPS (TTM)
$2.30
Dividend yield
—
52W range
$14 – $28
Volume
1.9M
ACADIA Pharmaceuticals Inc (ACAD) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+83.3%
Last 4 quarters
Revenue YoY growth
+9.4%
Most recent quarter
EPS YoY growth
-84.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.0%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-8.4%
2026-03-02
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-02 | $0.14 | -1.0% | $24.56 | $22.50 | -8.4% |
| 2025-11-05 | $0.42 | +200.0% | $21.85 | $21.65 | -0.9% |
| 2025-08-07 | $0.16 | +14.3% | $23.80 | $24.60 | +3.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.14 | $0.14 | -1.0% | $283.99M | +9.4% |
| 2025-09-30 | $0.14 | $0.42 | +200.0% | $278.63M | +11.3% |
| 2025-06-30 | $0.14 | $0.16 | +14.3% | $264.57M | +9.3% |
| 2025-03-31 | $0.05 | $0.11 | +120.0% | $244.32M | +18.7% |
| 2024-12-31 | $0.22 | $0.86 | +292.7% | $259.60M | +12.4% |
| 2024-09-30 | $0.14 | $0.20 | +42.9% | $250.40M | +18.3% |
| 2024-06-30 | $0.18 | $0.20 | +11.1% | $241.96M | +46.4% |
| 2024-03-31 | $0.05 | $0.10 | +100.0% | $205.83M | — |
| 2023-12-31 | $0.30 | $0.28 | -6.7% | $231.04M | — |
| 2023-09-30 | $-0.43 | $-0.40 | +7.0% | $211.70M | — |
| 2023-06-30 | $-0.08 | $0.01 | +112.5% | $165.24M | — |
Frequently asked questions
Has ACADIA Pharmaceuticals Inc beaten earnings estimates?
ACADIA Pharmaceuticals Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +83.3% over the last 4 quarters.
How does ACAD stock react to earnings?
ACAD stock has moved an average of -2.0% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is ACADIA Pharmaceuticals Inc's revenue growth rate?
ACADIA Pharmaceuticals Inc reported year-over-year revenue growth of +9.4% in its most recent quarter, with EPS growing -84.0% year-over-year.